Adagene (ADAG) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Invivyd (IVVD) over the past year, gaining 42.2% versus a loss of 57.3%. Over five years, ADAG leads with a -76.2% price change compared with -97.8% for IVVD. Invivyd is the larger company by market cap ($216.1 million vs $179.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | IVVD |
|---|---|---|
| Share price | $2.67 | $0.733 |
| Market cap | $179.27M | $216.06M |
| 1-day change | -3.96% | +4.65% |
| YTD return | +47.09% | -71.64% |
| 1-year return | +42.20% | -57.29% |
| 5-year return | -76.24% | -97.84% |
| EPS (TTM) | $-0.37 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $3.07 |
| 52-week low | $1.30 | $0.528 |
| Distance from 52-week high | -44.95% | -76.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +271.16% | +1264.26% |
| Average volume | 244.76K | 4.90M |
| Shares outstanding | 67.14M | 294.76M |
| Employees | 128 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed IVVD by 99.5 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
ADAG vs IVVD FAQ
Which is bigger, Adagene or Invivyd?
Invivyd (IVVD) is larger, with a market capitalization of $216.06M compared with $179.27M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or IVVD?
ADAG returned +42.20% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Invivyd in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Adagene and Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd.